These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 4827049)

  • 21. [BLOOD COAGULATION CHANGES AND THEIR RELATION TO THE EFFECT OF DRUGS IN HYPERTENSION].
    URBANIUK KG
    Kardiologiia; 1964; 4():45-8. PubMed ID: 14203916
    [No Abstract]   [Full Text] [Related]  

  • 22. Heparin dosage in extracorporeal circulation and its neutralization.
    Nyman D; Thurnherr N; Duckert F
    Thromb Diath Haemorrh; 1975 Feb; 33(1):102-4. PubMed ID: 1118825
    [No Abstract]   [Full Text] [Related]  

  • 23. Results of low-dose heparin prophylaxis of venous thrombosis considering plasma heparin and anti-thrombin III concentration.
    Tilsner V; Müller U; Reuter H; Raedler A
    Thromb Res; 1980 Feb 1-15; 17(3-4):519-25. PubMed ID: 7368173
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficiency and limits of blood coagulation tests].
    Róka L
    Internist (Berl); 1973 Apr; 14(4):149-53. PubMed ID: 4577209
    [No Abstract]   [Full Text] [Related]  

  • 25. Guidelines for heparin therapy.
    Genton E
    Ann Intern Med; 1974 Jan; 80(1):77-82. PubMed ID: 4589514
    [No Abstract]   [Full Text] [Related]  

  • 26. Letter: Protamine-corrected thrombin time.
    Palkuti H; Kales AN
    Am J Clin Pathol; 1974 May; 61(5):730-1. PubMed ID: 4827056
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of a centrifugal analyzer in coagulation testing.
    Hills LP; Lorenzi-Anderson M; Huey EE; Tiffany TO
    Semin Thromb Hemost; 1983 Jul; 9(3):217-27. PubMed ID: 6612352
    [No Abstract]   [Full Text] [Related]  

  • 28. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
    Raby C
    Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of Reptilase R and thrombin clotting time in the presence of fibrinogen degradation products and heparin.
    Latallo ZS; Teisseyre E
    Scand J Haematol Suppl; 1971; 13():261-6. PubMed ID: 5290690
    [No Abstract]   [Full Text] [Related]  

  • 30. [Mechanism of prolonged hypocoagulation appearing after intratracheal administration of heparin].
    Efimov VS; Rumiantseva AG; Golovleva OA; Rozkin MIa
    Biull Eksp Biol Med; 1992 May; 113(5):509-12. PubMed ID: 1421273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts: the use of heparin.
    Deykin D
    N Engl J Med; 1969 Apr; 280(17):937-8. PubMed ID: 5775632
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioequivalence of subcutaneous calcium and sodium heparins.
    Bender F; Aronson L; Hougie C; Moser K
    Clin Pharmacol Ther; 1980 Feb; 27(2):224-9. PubMed ID: 7353344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Heparin level and coagulation potential after subcutaneous injection of 7500 international units of heparin calcium].
    Briel RC
    Dtsch Med Wochenschr; 1984 Jun; 109(25):993-6. PubMed ID: 6734457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin therapy.
    Raich PC; Hahn MF; Korst DR
    Am Fam Physician; 1974 Sep; 10(3):163-8. PubMed ID: 4413661
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis.
    Banerjee RN; Kumar V; Sahni AL
    Indian J Med Res; 1972 Oct; 60(10):1432-42. PubMed ID: 4661652
    [No Abstract]   [Full Text] [Related]  

  • 36. Heparin assay methods for control of in vivo heparin effects.
    Godal HC
    Thromb Diath Haemorrh; 1975 Feb; 33(1):77-80. PubMed ID: 1091021
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The kinetics of heparin.
    Estes JW
    Ann N Y Acad Sci; 1971 Jul; 179():187-204. PubMed ID: 5285374
    [No Abstract]   [Full Text] [Related]  

  • 39. Statistical comparison of the automated activated partial thromboplastin time and the clotting time in the regulation of heparin therapy.
    Colman RW; Oxley L; Giannusa P
    Am J Clin Pathol; 1970 Jun; 53(6):904-7. PubMed ID: 5504609
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical value of a new method of therapeutic control of heparin].
    Pizzuto J; Garcia S; de la Paz Reyna M; Morales MR; Avilés A; Zavala B; Ponce L; Gaos C
    Arch Inst Cardiol Mex; 1978; 48(2):373-86. PubMed ID: 666447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.